These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 23677550)
1. The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. McDonald CM; Henricson EK; Abresch RT; Han JJ; Escolar DM; Florence JM; Duong T; Arrieta A; Clemens PR; Hoffman EP; Cnaan A; Muscle Nerve; 2013 Jul; 48(1):32-54. PubMed ID: 23677550 [TBL] [Abstract][Full Text] [Related]
2. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Henricson EK; Abresch RT; Cnaan A; Hu F; Duong T; Arrieta A; Han J; Escolar DM; Florence JM; Clemens PR; Hoffman EP; McDonald CM; Muscle Nerve; 2013 Jul; 48(1):55-67. PubMed ID: 23649481 [TBL] [Abstract][Full Text] [Related]
3. Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids. Duong T; Canbek J; Fernandez-Fernandez A; Henricson E; Birkmeier M; Siener C; Tesi Rocha C; McDonald C; Gordish-Dressman H; J Neuromuscul Dis; 2022; 9(1):147-159. PubMed ID: 34719507 [TBL] [Abstract][Full Text] [Related]
4. Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Spurney C; Shimizu R; Morgenroth LP; Kolski H; Gordish-Dressman H; Clemens PR; Muscle Nerve; 2014 Aug; 50(2):250-6. PubMed ID: 24395289 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ; JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703 [TBL] [Abstract][Full Text] [Related]
7. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Bello L; Gordish-Dressman H; Morgenroth LP; Henricson EK; Duong T; Hoffman EP; Cnaan A; McDonald CM; Neurology; 2015 Sep; 85(12):1048-55. PubMed ID: 26311750 [TBL] [Abstract][Full Text] [Related]
8. Genetic modifiers of respiratory function in Duchenne muscular dystrophy. Bello L; D'Angelo G; Villa M; Fusto A; Vianello S; Merlo B; Sabbatini D; Barp A; Gandossini S; Magri F; Comi GP; Pedemonte M; Tacchetti P; Lanzillotta V; Trucco F; D'Amico A; Bertini E; Astrea G; Politano L; Masson R; Baranello G; Albamonte E; De Mattia E; Rao F; Sansone VA; Previtali S; Messina S; Vita GL; Berardinelli A; Mongini T; Pini A; Pane M; Mercuri E; Vianello A; Bruno C; Hoffman EP; Morgenroth L; Gordish-Dressman H; McDonald CM; ; Pegoraro E Ann Clin Transl Neurol; 2020 May; 7(5):786-798. PubMed ID: 32343055 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids. McDonald CM; Gordish-Dressman H; Henricson EK; Duong T; Joyce NC; Jhawar S; Leinonen M; Hsu F; Connolly AM; Cnaan A; Abresch RT; Neuromuscul Disord; 2018 Nov; 28(11):897-909. PubMed ID: 30336970 [TBL] [Abstract][Full Text] [Related]
10. Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study. Bello L; Kesari A; Gordish-Dressman H; Cnaan A; Morgenroth LP; Punetha J; Duong T; Henricson EK; Pegoraro E; McDonald CM; Hoffman EP; Ann Neurol; 2015 Apr; 77(4):684-96. PubMed ID: 25641372 [TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Manzur AY; Kuntzer T; Pike M; Swan A Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM; PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407 [TBL] [Abstract][Full Text] [Related]
13. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Bello L; Morgenroth LP; Gordish-Dressman H; Hoffman EP; McDonald CM; Cirak S; Neurology; 2016 Jul; 87(4):401-9. PubMed ID: 27343068 [TBL] [Abstract][Full Text] [Related]
14. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests. Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653 [TBL] [Abstract][Full Text] [Related]
15. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F; J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532 [TBL] [Abstract][Full Text] [Related]
16. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database. Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC; JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644 [TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Manzur AY; Kuntzer T; Pike M; Swan A Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215 [TBL] [Abstract][Full Text] [Related]
18. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H; Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study. Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; McDonald CM; Smith EC; Zaidman CM; Nakagawa T; ; Hoffman EP J Neuromuscul Dis; 2023; 10(3):439-447. PubMed ID: 37005891 [TBL] [Abstract][Full Text] [Related]
20. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy. Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]